Clinical Trial Update: Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating tisleizumab (BGB-A317) for dMMR/MSI-H colorectal cancer patients prior to surgery; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• tisleizumab (tisleizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: DMMR Colorectal Cancer, Anti PD-1 | Phase 2 | Status: UNKNOWN